Should I Buy EPRX? EPRX 2026 Analysis

Should You Buy Eupraxia Pharmaceuticals Inc (EPRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

7.600

1 Day change

1.20%

52 Week Range

9.320

Analysis Updated At

2026/03/13

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Eupraxia Pharmaceuticals Inc (EPRX) is not a strong buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The lack of positive financial growth, absence of trading signals, neutral trading trends, and no significant news or catalysts make this stock a hold rather than a buy at the moment.

Technical Analysis

The MACD histogram is negative and expanding, indicating bearish momentum. RSI is at 28.099, which is neutral but close to oversold territory. The stock is trading below its pivot level of 7.99, with support at 7.598 and resistance at 8.381. Overall, the technical indicators do not suggest a strong buying opportunity.

Positive Catalysts

NULL identified. No recent news, no significant insider or hedge fund activity, and no congress trading data.

Neutral/Negative Catalysts

The stock has a 60% chance to decline by -0.76% in the next day and lacks strong financial performance or growth indicators. The MACD shows bearish momentum, and the market sentiment is neutral.

Financial Performance

In Q3 2025, revenue remained at 0 with no YoY growth. Net income improved slightly to -6,361,367 (up 7.03% YoY), but EPS remained negative at -0.17 with no growth. Gross margin is 0, indicating no profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available on analyst ratings or price target changes.

4 Analyst Rating

Wall Street analysts forecast EPRX stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 7.510

Low

11.02

Averages

13.02

High

16.03

Current: 7.510

Low

11.02

Averages

13.02

High

16.03

H.C. Wainwright

Brandon Folkes

Buy

downgrade

$12 -> $11

AI Analysis

2026-03-17

New

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$12 -> $11

AI Analysis

2026-03-17

New

downgrade

Buy

Reason

H.C. Wainwright analyst Brandon Folkes lowered the firm's price target on Eupraxia Pharmaceuticals to $11 from $12 and keeps a Buy rating on the shares. The firm adjusted the company's model post the Q4 report. The Phase 2b RESOLVE study remains on track for a Q3 readout, which is the next key catalyst for the program, the analyst tells investors in a research note.

H.C. Wainwright

Buy

maintain

$12

2025-08-20

Reason

H.C. Wainwright

Price Target

$12

2025-08-20

maintain

Buy

Reason

H.C. Wainwright believes Celldex's (CLDX) Phase 2 data for barzolvolimab in patients with eosinophilic esophagitis supports the positive thesis on Eupraxia Pharmaceuticals (EPRX). Barzolvolimab did not show improvements in eosinophilic esophagitis symptoms or endoscopic measures of disease activity compared to placebo, the analyst tells investors in a research note. The firm says a potential competitor to Eupraxia in eosinophilic esophagitis has been removed. The barzolvolimab study also validates the "simpler but more effective approach" Eupraxia is taking with EP-104GI, contends H.C. Wainwright. The firm has a Buy rating on the shares with a $12 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EPRX

Unlock Now

EPRX Should I Buy

EPRX Should I Buy

Should You Buy Eupraxia Pharmaceuticals Inc (EPRX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch